Abstract Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constitutively activated kinase, which causes chronic myelogenous leukemia (CML). Here we report the first almost complete backbone assignment of c-ABL kinase domain in complex with imatinib.
kinase domain, is one such important drug target, which has been clinically validated by imatinib (Glivec; Novartis Pharma AG), an efficacious and well-tolerated treatment for chronic myelogenous leukemia (CML) (Ren 2005) . Much structural knowledge on ABL-inhibitor complexes has been generated using X-ray crystallography (Nagar et al. 2002; Cowan-Jacob et al. 2007 ), but very little is known about the solution structure and dynamics of ABL kinase.
To enable NMR studies on the solution behavior of ABL kinase, we have obtained backbone resonance assignment of ABL kinase domain in complex with imatinib. The selected construct of the ABL kinase domain (denoted here as ABL, residues GAMDP-S229-S500) contains 277 residues and has a typical kinase bilobal structure, with the N-terminal lobe containing b-sheets and the conserved helix C, and the C-terminal lobe being mainly helical. At the interface of the two lobes is the ATP-binding pocket, which is also the binding site of most ABL inhibitors.
Methods and materials
Since ABL is not readily expressed in E. coli, we have developed a protocol for the 13 C/ 15 N isotope labeling of the ABL kinase catalytic domain in Baculovirus-infected insect cells, either uniformly or selectively for certain amino acid types (Strauss et al. 2003; Strauss et al. 2005) .
Uniformly 13 C, 15 N or selectively labeled samples (Strauss et al. 2003; Strauss et al. 2005 ) of the ABLimatinib complex were prepared as 0.4 mM solutions in 250 ll (Shigemi microtubes) of buffer containing 95% H 2 O, 5% D 2 O, 20 mM BisTris, 100 mM NaCl, 2 mM EDTA, 3 mM DTT at pH 6.5 with an ABL:imatinib ratio of 1:1. NMR spectra were recorded at 293 K on Bruker DRX 600 (cryo or room temperature probe) or DRX 800 MHz (cryoprobe) spectrometers. Due to the lack of deuteration, the sensitivity of NMR experiments involving 13 C b or other side chain nuclei was very low. Therefore, backbone assignments had to be performed with non-TROSY versions of the HNCO, HNCA, HN(CO)CA (Grzesiek and Bax 1992) , and an 15 N-edited 1 H-1 H NOESY. The assignment was aided and verified by spectra of a total of 15 selectively labeled samples that had 15 N, 13 C a and 13 C' nuclei introduced specifically for certain amino acid types (see supplementary material Table 1 ). All NMR data were processed and analysed using the NMRPipe (Delaglio et al. 1995) and NMRView (Johnson and Blevins 1994) CO resonances, covering 254 of the 264 non-proline residues (Fig. 1) . Unassigned residues consist of the N-terminal glycine, seven residues within the activation loop (consisting of residues D381-P402), and H361. Line broadening of adjacent residues indicates that most of the missing residues are broadened beyond detection due to intermediate conformational exchange. Despite the difficulty in observing the entire activation loop, the assignments include at least 14 key residues involved in ligand binding. The assignments have been deposited in the BMRB (accession number 15488). I293   K415   N368   L266   V448   A365   Y353   L411   L471   L376   V339   T389   S385   I360   Y320   K419  S265   R328  C475 D381   K357   T392  T319   L340   C305   I313  E431   F425   I418   L370   T243  L428   W478  T267  L445  K274  H295   D444   I314  M244  R239   M237   Q300   Y257   L302   L364   E466   E255 K262 A407   R332   K271   W261   A366   D363   T306   N297   F486   E409   S417  T315   D421   K294   A380   L301   G321   G251  G303   T240   G436   G398   G426   G250   K375   V304   G390   G383   G442  S446   S485   S481   G254   T277  R473   D455  M451  C369  H246  N358   E329   T495   E308   V468   V338   S410   R457   A350   S348  Y253   V270   L248   A399   F283   G372   K467   Y312   N374   Q477   T406   E316   Y440   R483   E334   M437   I443 
